Aims: To compare the value of serial electrocardiographic (ECG) changes by the two most widely used ECG classification systems-the Minnesota Code (MC) and Novacode (Nova) for the prediction of subsequent coronary heart disease (CHD) and total mortality. Methods and results: We studied 12-lead ECGs from 12,477 participants (average age 54 years at baseline; 58% women; 76% non-Hispanic white) in the Atherosclerosis Risk in Communities (ARIC) Study, who were free of CHD at baseline in 1987, had both good-quality ECGs at baseline and at first study-scheduled follow-up visit, and had ECG QRS duration <120 ms. A total 2119 participants died (17%), including 280 CHD deaths during an average 17-year follow up. Cox regression models assessed outcome associated with significant serial ECG changes by MC and Nova separately. For CHD death the hazard ratio was 6.8 (95% CI 3.5-13.3) for incident Nova myocardial infarction (MI), and 5.7 (95% CI 2.7-11.9) for MC-MI in a multivariable model adjusted for clinical and demographic characteristics, and ECG left ventricular hypertrophy. The increased risk for total mortality doubled for both Nova and MC serial ECG MI. Major evolving ST-T wave abnormalities alone were associated with a !132% increased risk for CHD death and a 50% increased risk for total mortality by either Nova or MC. Conclusion: ECG serial change by both MC and Nova are equally valuable predictors for future fatal cardiac events and total mortality and hence equally useful prognostic indicators in clinical trials and epidemiological studies.
Well-defined criteria for clinically significant evolution of electrocardiographic (ECG) abnormalities are frequently called for. [1] [2] [3] [4] The Minnesota Code (MC) was originally developed to determine cardiac-related disease prevalence in population studies in the early 1960s. 5 Later, criteria were developed to document incident events using objective side-by-side ECG comparison rules. 6, 7 The Novacode (Nova) is an extension of the MC, 8, 9 which provides a comprehensive hierarchical set of criteria for both prevalent ECG abnormalities and clinically significant serial ECG changes. Both systems have been used in many epidemiological studies and clinical trials. We have previously compared MC and Nova in terms of their ability to detect prevalent ECG abnormalities in men and women separately and how these ECG abnormalities are predictive of future cardiovascular disease (CVD) events. 10, 11 In the present study, we compared the value of serial ECG changes as detected by MC and Nova to predict subsequent incident fatal cardiac events and total mortality.
Methods

Study population
The Atherosclerosis Risk In Communities (ARIC) Study, is a population-based, multicentre prospective study to investigate the natural history and aetiology of atherosclerotic and CVD events from four US communities in Maryland, Minnesota, Mississippi, and North Carolina (n ¼ 15,792 men and women aged 45-64 years at enrolment). Participants were interviewed at home, and invited to a baseline clinical examination (1987-89). They attended three further clinical examinations at approximately 3-year intervals, and received a follow-up telephone call yearly. Details of study design, protocol, sampling procedures, and selection and exclusion criteria have been published. 12 After excluding the participants with prevalent coronary heart disease (CHD) [ECG evidence or a history of myocardial infarction (MI)], angina, coronary artery bypass surgery, coronary angioplasty, or congestive heart failure at baseline, we only focused on those participants who had both good-quality ECGs at baseline and at first study-scheduled follow-up visit (at year 4), and had ECG QRS duration <120 ms. There remained 12, 477 participants for the present study (Supplementary Figure 1 , available online).
Outcome ascertainment
Relevant outcomes were incident CHD deaths and allcause mortality. Deaths and hospitalization events were ascertained using annual follow-up calls to the cohort members, review of vital records, and community surveillance of hospitalized and fatal events. A CHD death was defined as lacking a probable non-CHD cause, and occurring in the context of a recent MI, chest pain within 72 hours of death, or a history of CHD occurring from the first triennial follow-up visit to 31 December 2006 with an average 17-year follow up. Events were classified independently by a separate committee. Detailed definitions for the diagnosis of acute MI and death due to CHD have been published. 13, 14 
ECG methodology
Identical electrocardiographs (MAC PC; Marquette Electronics Inc., Milwaukee, Wisconsin, USA) were used in all clinic sites, and resting 10-second standard simultaneous 12-lead ECGs were recorded in all participants using strictly standardized procedures. The chest electrodes were located in precise positions. All ECGs were processed in a central ECG laboratory (EPICORE Center, University of Alberta, Edmonton, Canada, and later at EPICARE Center, Wake Forest University, Winston-Salem, USA), where they were visually inspected for technical errors and inadequate quality. The ECGs first processed by the Dalhousie ECG program were repeated for the present study using the 2001 version of the GE Marquette 12SL program (Marquette 12SL ECG Physician Guide available at www.ge-healthcare.com). ECGs were classified according to the Nova and MC using variables derived from the median complex of the Marquette measurement matrix.
ECG serial classification criteria for incident MI/ischaemia
Serial change Nova classification of incident MI/ischaemia is based on the change of a score in the appearance of the duration and/or voltage of the Q-wave exceeding specified limits and on whether an ST-segment and T-wave abnormality have evolved significantly from the reference ECG. 7, 9 Nova classifies incident MI/ ischaemia as I-Nova-5 (I for 'incident') with eight hierarchies: incident Nova-MI was identified by I-Nova-5.1 to I-Nova-5.4, and I-Nova-5.5/5.6 was for isolated incident ECG ischaemia by Nova (Table 1 and  Supplementary Table 1) .
MC for classification of incident MI/ischaemia incorporates four MC codes: code 1 for Q and QS patterns, code 4 for ST-segment depression, code 5 for T-wave negativity, and code 9-2 for ST-segment elevation. All serial changes were confirmed by side-by-side ECG comparison of Q and ST-T change between the first and subsequent examinations. Serial change MC categorizes evolving Q codes as Q1 to Q8, and for evolving ST-T codes as STE-1, ST-T1 to ST-T7. [5] [6] [7] Additionally, in order to achieve equivalency with the I-Nova-5 code, eight hierarchic levels from I-MC-C.1 to I-MC-C.7 were combined (Table 1 and  Supplementary Table 2 ). Incident MC-MI was identified either by Q1 to Q7, or I-MC-C.1 to I-MC-C.4, and I-MC-C5/C.6 was for isolated incident ECG ischaemia by MC.
One difference between the Nova and MC is that Q-wave smaller than 100 mV are ignored in the MC, whereas Nova scores Q-waves that are at least 20 ms in duration and 75 mV in amplitude.
Statistical analysis
Frequency distributions of all ECG and non-ECG variables were first inspected to rule out anomalies and outliers possibly due to measurement artefacts. Descriptive statistics were used to determine mean, standard deviations, and percentiles for continuous variables, and frequencies and percentages for categorical variables. Cox's proportional hazards analysis was used to assess the effects of serial change ECG variables on the risk of CHD death and total mortality, and comparison of MC or Nova predictors. Univariate and multivariate models were used in the analysis. Multivariate mode adjusted for the key demographic and clinical characteristics which included education, smoking status, alcohol use, hypertension, diabetes mellitus, history of cancer, body mass index, systolic blood pressure, white blood cell, high-density lipoprotein, low-density lipoprotein, baseline glucose, insulin, fibrinogen, uric acid, creatinine, geographic regions, and ECG left ventricular hypertrophy (ECG-LVH) by MC/Nova -all defined in previous reports. 7, [12] [13] [14] Analyses were performed with SAS version 9.1.3 (SAS Institute, Cary, North Carolina, USA).
Results
Among 12,477 participants with ECGs both at baseline and at first triennial visit, the mean age at baseline was 54 years and there were 58% women and 76% nonHispanic white. Of these, 32% had hypertension, 10% diabetes, and 5% major ECG ST-T abnormalities by either Nova or MC (3.6% by Nova and 3.8% by MC). During an average 17-year post-first follow-up visit, total mortality was 17.0% (2119) and CHD death was 2.2% (280) ( Table 2) . Table 2 
Prognosis of new ECG MI for CHD death and total mortality
New incident ECG MI categories were strong predictors for CHD death and all-cause mortality (Tables 3  and 4 ). Incident ECG MI by MC/Nova criteria had at least a 5.6 times higher [hazard ratio (HR) 6.81, 95% confidence interval (CI) 3.49-13.3 for Nova, and HR 5.66, 95% CI 2.70-11.9 for MC] in the multivariate models adjusted for demographic and clinical variables and ECG-LVH. Incident ECG MI by MC/Nova criteria doubled the risk for total mortality in all models (Table 4) .
Isolated incident ECG ischaemia independently predicting CHD death and total mortality
Compared with incident ECG MI, major evolution of ST-T change alone was also a strong predictor for CHD death and total mortality (Tables 3 and 4) . There was a 2-4-times increased risk for CHD death (HR 2.32, 95% CI 1.31-4.08 for I-Nova-5.5/5.6; and HR 2.55, 95% CI 1.69-3.84 for I-MC-C.5/C.6). There was about 50% increased risk for total mortality by I-MC-C.5/C.6 or I-Nova-5.5/5.6 in the multivariate model. In summary, any new Q/ST-T serial change has !168% increased risk for CHD death and !47% increase risk for total mortality by either Nova or MC serial classification compared with no new Q/ST-T change group. There was an interaction between the diagnosis of a clinical MI by the diagnostic committee and the appearance of a serial ECG MI or major Q/ST-T evolution at the first follow-up visit. ECG evolving new MI or major Q/ST-T with diagnostic clinic CHD MI (Supplementary Tables 3 and 4 ) increased the risk of CHD death by 7.5 times (HR 8.57, 95% CI 5.04-14.6) Values are mean AE SD or n (%). See Table 1 
Discussion
Cardiovascular disease is a major cause of death and disability worldwide 15 with the ECG contributing independent diagnostic and prognostic information. [16] [17] [18] [19] [20] [21] Serial change classification for incident MI/ischaemia by MC or Nova has played an important role in numerous clinical trials and epidemiological studies. [5] [6] [7] [8] [9] [10] [11] 21 Coding by either Nova or MC has been well suited for incorporation in computer analysis programs as well as by visual review. This is the first study to evaluate and compare the predictive power of serial change criteria by these two ECG classification systems. The relative strength of the two systems for prediction of the separate endpoints of CHD death and total mortality varied slightly.
Evolving Q-wave or ST-T as evidence of an incident MI or ischaemic event has been demonstrated previously in publications that have related ECG serial change to CHD death and total mortality. including the Multiple Risk Factor Intervention Trial (MRFIT) 6 and the Framingham study. 21 New incident ECG MI (with a major evolving Q-wave or evolving minor Q-wave plus evolving ST-T change) had a fourtimes higher related risk for coronary mortality in the MRFIT. The present study showed that new incident ECG MI increased by five times the risk for CHD death compared with those without any evolving Q/ST-T and doubled the risk for total mortality.
In the present study, 95% (523/552) of MC evolving ST categories were documented as ST-T1, ST-T3, and ST-T7 (major T-wave inversion to major T-wave inversion with 100% increase) and showed similar or higher risks than in MRFIT. The adjusted relative risks for CHD death in the present study were HRs 4.13, 1.82, and 3.31, respectively; and 2.29, 1.30, and 1.75 for total mortality. The combined code for all of isolated evolving ST-T categories had a HR 2.55 by MC, and 2.32 by Nova for CHD death. According this study, the Minnesota Code serial changes include more patients without apparent loss of specificity.
Study strengths and limitations
We focused only on electronic ECG data. Also, the serial change was between the baseline examination and the first follow-up exam that did not occur until 3 years later, so that it did not test those changes that might have occurred and regressed in the first 2 years of the study. The strength of the study is the large community-based population, long-term follow up, standardized ECG recording, and adjudicated outcomes.
Conclusions
ECG serial change criteria by both MC and Nova are equally valuable classification systems for detection of incident MI/ischaemia in clinical trials and epidemiological studies. Any incident ECG MI or isolated major evolving ST-T changes by Nova or MC are independent predictors for fatal cardiac events and all-cause mortality.
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